Pfizer has said it is to buy US cancer drug firm Medivation, after winning an auction against rivals including Sanofi, confirming widespread press speculation. Pfizer will pay a premium of ...

Pfizer has emerged as the next potential suitor for oncology firm, Medivation, which has developed the prostate cancer drug, Xtandi (enzalutamide). Last week Medivation rejected a $9.3 billion bid ...

Medivation agreed in July to court acquisition offers from ... The deal, which is expected to be finalized by the third or fourth quarter of this year, could be a boost for Pfizer following its failed ...